A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17)

PURPOSE: The sequence of taxanes (T) followed by anthracyclines (A) as neoadjuvant chemotherapy has been the standard of care for almost 20 years for locally advanced breast cancer (LABC). Sequential administration of eribulin (E) following A/T could provide a greater response rate for women with LA...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukada, Ippei, Ito, Yoshinori, Kondo, Naoto, Ohtani, Shoichiro, Hattori, Masaya, Tokunaga, Eriko, Matsunami, Nobuki, Mashino, Kohjiro, Kosaka, Taijiro, Tanabe, Masahiko, Yotsumoto, Daisuke, Yamanouchi, Kosho, Sawaki, Masataka, Kashiwaba, Masahiro, Kawabata, Hidetaka, Kuroi, Katsumasa, Morita, Satoshi, Ohno, Shinji, Toi, Masakazu, Masuda, Norikazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558278/
https://www.ncbi.nlm.nih.gov/pubmed/34554370
http://dx.doi.org/10.1007/s10549-021-06396-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558278/
https://www.ncbi.nlm.nih.gov/pubmed/34554370
http://dx.doi.org/10.1007/s10549-021-06396-0

Ejemplares similares